Effect of systemic glucocorticoid therapy on bone metabolism: an update

References

• Cooper MS. Sensitivity of bone to glucocorticoids. Clin. Sci. 107, 111–123 (2004).
   PubMed Web of Science ®Google Scholar
• Canalis E. Clinical review 83: mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J. Clin. Endocrinol. Metab. 81, 3441–3447 (1996).
   PubMed Web of Science ®Google Scholar
• Godschalk MF, Downs RW. Effect of short-term glucocorticoids on serum osteocalcin in healthy young men. J. Bone Miner. Res. 3, 113–115 (1988).
   PubMed Web of Science ®Google Scholar
• Gennari C, Imbimbo B. Effects of prednisone and deflazacort on vertebral bone mass. Calcif. Tissue Int. 37, 592–593 (1985).
   PubMed Web of Science ®Google Scholar
• Adachi JD, Bensen WG, Brown J et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N. Engl. J. Med. 337, 382–387 (1997).
   PubMed Web of Science ®Google Scholar
• Cohen S, Levy RM, Keller M et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 42, 2309–2318 (1999).
   PubMed Web of Science ®Google Scholar
• Saag KG, Emkey R, Schnitzer TJ et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N. Engl. J. Med. 339, 292–299 (1998).
   PubMed Web of Science ®Google Scholar
• Wallach S, Cohen S, Reid DM et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif. Tissue Int. 67, 277–285 (2000).
   PubMed Web of Science ®Google Scholar
• Carbonare LD, Arlot ME, Chavassieux PM, Roux JP, Portero NR, Meunier PJ. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J. Bone Miner. Res. 16, 97–103 (2001).
   PubMed Web of Science ®Google Scholar
• Vedi S, Elkin SL, Compston JE. A histomorphometric study of cortical bone of the iliac crest in patients treated with glucocorticoids. Calcif. Tissue Int. 77(2), 79–83 (2005).
   PubMed Web of Science ®Google Scholar
• Sambrook PN, Hughes DR, Nelson AE, Robinson BG, Mason RS. Osteocyte viability with glucocorticoid treatment: relation to histomorphometry. Ann. Rheum. Dis. 62, 1215–1217 (2003).
   PubMed Web of Science ®Google Scholar
• Leonard MB, Feldman HI, Shults J, Zemel BS, Foster BJ, Stallings VA. Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome. N. Engl. J. Med. 351, 868–875 (2004).
   PubMed Web of Science ®Google Scholar
• Cooper MS, Stewart PM. Glucocorticoids and bone mineral content in the childhood nephrotic syndrome. N. Engl. J. Med. 351, 2655–2657 (2004).
   PubMedGoogle Scholar
• Cooper MS, Hewison M, Stewart PM. Glucocorticoid activity, inactivity and the osteoblast. J. Endocrinol. 163, 159–164 (1999).
   PubMed Web of Science ®Google Scholar
• Chang DJ, Ji C, Kim KK, Casinghino S, McCarthy TL, Centrella M. Reduction in transforming growth factor β receptor I expression and transcription factor CBFα1 on bone cells by glucocorticoid. J. Biol. Chem. 273, 4892–4896 (1998).
   PubMed Web of Science ®Google Scholar
• Engelbrecht Y, de Wet H, Horsch K, Langeveldt CR, Hough FS, Hulley PA. Glucocorticoids induce rapid upregulation of mitogen-activated protein kinase phosphatase-1 and dephosphorylation of extracellular signal-regulated kinase and impair proliferation in human and mouse osteoblast cell lines. Endocrinology 144, 412–422 (2003).
   PubMed Web of Science ®Google Scholar
• Rubin MR, Bilezikian JP. Clinical review 151: the role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence. J. Clin. Endocrinol. Metab. 87, 4033–4041 (2002).
   PubMed Web of Science ®Google Scholar
• Boden SD, Hair G, Titus L et al. Glucocorticoid-induced differentiation of fetal rat calvarial osteoblasts is mediated by bone morphogenetic protein-6. Endocrinology 138, 2820–2828 (1997).
   PubMed Web of Science ®Google Scholar
• Pereira RM, Delany AM, Durant D, Canalis E. Cortisol regulates the expression of Notch in osteoblasts. J. Cell Biochem. 85, 252–258 (2002).
   PubMed Web of Science ®Google Scholar
• McCarthy TL, Ji C, Chen Y, Kim K, Centrella M. Time- and dose-related interactions between glucocorticoid and cyclic adenosine 3’,5’-monophosphate on CCAAT/enhancer-binding protein-dependent insulin-like growth Factor I expression by osteoblasts. Endocrinology 141, 127–137 (2000).
   PubMed Web of Science ®Google Scholar
• Ohnaka K, Taniguchi H, Kawate H, Nawata H, Takayanagi R. Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid-induced osteoporosis. Biochem. Biophys. Res. Commun. 318, 259–264 (2004).
   PubMed Web of Science ®Google Scholar
• Wang FS, Lin CL, Chen YJ et al. Secreted frizzled-related protein 1 modulates glucocorticoid attenuation of osteogenic activities and bone mass. Endocrinology 146, 2415–2423 (2005).
   PubMed Web of Science ®Google Scholar
• Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J. Clin. Invest. 102, 274–282 (1998).
   PubMed Web of Science ®Google Scholar
• Kogianni G, Mann V, Ebetino F et al. Fas/CD95 is associated with glucocorticoid-induced osteocyte apoptosis. Life Sci. 75, 2879–2895 (2004).
   PubMed Web of Science ®Google Scholar
• Nakashima T, Sasaki H, Tsuboi M et al. Inhibitory effect of glucocorticoid for osteoblast apoptosis induced by activated peripheral blood mononuclear cells. Endocrinology 139, 2032–2040 (1998).
   PubMed Web of Science ®Google Scholar
• Pereira RM, Delany AM, Canalis E. Cortisol inhibits the differentiation and apoptosis of osteoblasts in culture. Bone 28, 484–490 (2001).
   PubMed Web of Science ®Google Scholar
• Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J. Clin. Invest. 104, 439–446 (1999).
   PubMed Web of Science ®Google Scholar
• Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J. Clin. Invest. 104, 1363–1374 (1999).
   PubMed Web of Science ®Google Scholar
• Weinstein RS, Chen JR, Powers CC et al. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J. Clin. Invest. 109, 1041–1048 (2002).
   PubMed Web of Science ®Google Scholar
• O’Brien CA, Jia D, Plotkin LI et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 145(4), 1835–1841 (2003).
   PubMed Web of Science ®Google Scholar
• Weinstein RS, Jia D, Powers CC et al. The skeletal effects of glucocorticoid excess override those of orchidectomy in mice. Endocrinology 145(4), 1980–1987 (2004).
   PubMed Web of Science ®Google Scholar
• Mankin HJ. Nontraumatic necrosis of bone (osteonecrosis). N. Engl. J. Med. 326, 1473–1479 (1992).
   PubMed Web of Science ®Google Scholar
• Williams PL, Corbett M. Avascular necrosis of bone complicating corticosteroid replacement therapy. Ann. Rheum. Dis. 42, 276–279 (1983).
   PubMed Web of Science ®Google Scholar
• Weinstein RS, Nicholas RW, Manolagas SC. Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J. Clin. Endocrinol. Metab. 85, 2907–2912 (2000).
   PubMed Web of Science ®Google Scholar
• Hofbauer LC, Gori F, Riggs BL et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140, 4382–4389 (1999).
   PubMed Web of Science ®Google Scholar
• Bekker PJ, Holloway DL, Rasmussen AS et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J. Bone Miner. Res. 19, 1059–1066 (2004).
   PubMed Web of Science ®Google Scholar
• Takuma A, Kaneda T, Sato T, Ninomiya S, Kumegawa M, Hakeda Y. Dexamethasone enhances osteoclast formation synergistically with transforming growth factor-β by stimulating the priming of osteoclast progenitors for differentiation into osteoclasts. J. Biol. Chem. 278, 44667–44674 (2003).
   PubMed Web of Science ®Google Scholar
• Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N. Engl. J. Med. 348, 727–734 (2003).
   PubMed Web of Science ®Google Scholar
• Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106, 1481–1488 (2000).
   PubMed Web of Science ®Google Scholar
• Tomlinson JW, Walker EA, Bujalska IJ et al. 11β-hydroxysteroid dehydrogenase Type 1: a tissue-specific regulator of glucocorticoid response. Endocr. Rev. 25, 831–866 (2004).
   PubMed Web of Science ®Google Scholar
• Cooper MS, Walker EA, Bland R, Fraser WD, Hewison M, Stewart PM. Expression and functional consequences of 11b-hydroxysteroid dehydrogenase activity in human bone. Bone 27, 375–381 (2000).
   PubMed Web of Science ®Google Scholar
• Cooper MS, Blumsohn A, Goddard PE et al. 11β-hydroxysteroid dehydrogenase Type 1 activity predicts the effects of glucocorticoids on bone. J. Clin. Endocrinol. Metab. 88, 3874–3877 (2003).
   PubMed Web of Science ®Google Scholar
• Cooper MS, Bujalska I, Rabbitt E et al. Modulation of 11β-hydroxysteroid dehydrogenase isozymes by pro-inflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. J. Bone Miner. Res. 16, 1037–1044 (2001).
   PubMed Web of Science ®Google Scholar
• Cooper MS, Rabbitt EH, Goddard PE, Bartlett WA, Hewison M, Stewart PM. Osteoblastic 11β-hydroxysteroid dehydrogenase Type 1 activity increases with age and glucocorticoid exposure. J. Bone Miner. Res. 17, 979–986 (2002).
   PubMed Web of Science ®Google Scholar
• Tobias JH, Sasi MR, Greenwood R, Probert CS. Rapid hip bone loss in active Crohn’s disease patients receiving short-term corticosteroid therapy. Aliment. Pharmacol. Ther. 20, 951–957 (2004).
   PubMed Web of Science ®Google Scholar
• van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C. Use of oral corticosteroids in the United Kingdom. QJM 93, 105–111 (2000).
   PubMed Web of Science ®Google Scholar
• van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J. Bone Miner. Res. 15, 993–1000 (2000).
   PubMed Web of Science ®Google Scholar
• Kanis JA, Borgstrom F, de Laet C et al. Assessment of fracture risk. Osteoporos. Int. 16, 581–589 (2005).
   PubMed Web of Science ®Google Scholar
• Manolagas SC. Corticosteroids and fractures: a close encounter of the third cell kind. J. Bone Miner. Res. 15, 1001–1005 (2000).
   PubMed Web of Science ®Google Scholar
• Compston J. Glucocorticoid-induced Osteoporosis: Guidelines for Prevention and Treatment. RCP, London, UK (2002).
   Google Scholar
• van Staa TP, Cooper C, Leufkens HG, Bishop N. Children and the risk of fractures caused by oral corticosteroids. J. Bone Miner. Res. 18, 913–918 (2003).
   PubMed Web of Science ®Google Scholar
• van Staa TP, Geusens P, Pols HA, de Laet C, Leufkens HG, Cooper C. A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM 98, 191–198 (2005).
   PubMed Web of Science ®Google Scholar
• Gluck OS, Murphy WA, Hahn TJ, Hahn B. Bone loss in adults receiving alternate day glucocorticoid therapy. A comparison with daily therapy. Arthritis Rheum. 24, 892–898 (1981).
   PubMed Web of Science ®Google Scholar
• Reid DM, Hughes RA, Laan RF et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J. Bone Miner. Res. 15, 1006–1013 (2000).
   PubMed Web of Science ®Google Scholar
• Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J. Bone Miner. Res. 16, 104–112 (2001).
   PubMed Web of Science ®Google Scholar
• Cauley JA, Robbins J, Chen Z et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 290, 1729–1738 (2003).
   PubMed Web of Science ®Google Scholar
• Reid IR, Wattie DJ, Evans MC, Stapleton JP. Testosterone therapy in glucocorticoid-treated men. Arch. Intern. Med. 156, 1173–1177 (1996).
   PubMed Web of Science ®Google Scholar
• Sambrook P, Birmingham J, Kelly P et al. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N. Engl. J. Med. 328, 1747–1752 (1993).
   PubMed Web of Science ®Google Scholar
• Reginster JY, Kuntz D, Verdickt W et al. Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporos. Int. 9, 75–81 (1999).
   PubMed Web of Science ®Google Scholar
• Sambrook PN, Kotowicz M, Nash P et al. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J. Bone Mineral. Res. 18, 919–924 (2003).
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344, 1434–1441 (2001).
   PubMed Web of Science ®Google Scholar
• Lane NE, Sanchez S, Modin GW, Genant HK, Ini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J. Clin. Invest. 102, 1627–1633 (1998).
   PubMed Web of Science ®Google Scholar
• Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J. Bone Miner. Res. 15, 944–951 (2000).
   PubMed Web of Science ®Google Scholar
• Riggs BL, Hodgson SF, O’Fallon WM et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N. Engl. J. Med. 322, 802–809 (1990).
   PubMed Web of Science ®Google Scholar
• Haguenauer D, Welch V, Shea B, Tugwell P, Adachi JD, Wells G. Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis. Osteoporos. Int. 11, 727–738 (2000).
   PubMed Web of Science ®Google Scholar
• Olgaard K, Storm T, van Wowern N et al. Glucocorticoid-induced osteoporosis in the lumbar spine, forearm, and mandible of nephrotic patients: a double-blind study on the high-dose, long-term effects of prednisone versus deflazacort. Calcif. Tissue Int. 50, 490–497 (1992).
   PubMed Web of Science ®Google Scholar
• Lippuner K, Casez JP, Horber FF, Jaeger P. Effects of deflazacort versus prednisone on bone mass, body composition, and lipid profile: a randomized, double-blind study in kidney transplant patients. J. Clin. Endocrinol. Metab. 83, 3795–3802 (1998).
   PubMed Web of Science ®Google Scholar
• Krogsgaard MR, Thamsborg G, Lund B. Changes in bone mass during low dose corticosteroid treatment in patients with polymyalgia rheumatica: a double-blind, prospective comparison between prednisolone and deflazacort. Ann. Rheum. Dis. 55, 143–146 (1996).
   PubMed Web of Science ®Google Scholar
• Diederich S, Eigendorff E, Burkhardt P et al. 11β-hydroxysteroid dehydrogenase types 1 and 2: an important pharmacokinetic determinant for the activity of synthetic mine. J. Clin. Endocrinol. Metab. 87, 5695–5701 (2002).
   PubMed Web of Science ®Google Scholar
• Hodson EM, Knight JF, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst. Rev. CD001533 (2005).
   Google Scholar
• Reichardt HM, Kaestner KH, Tuckermann J et al. DNA binding of the glucocorticoid receptor is not essential for survival. Cell 93, 531–541 (1998).
   PubMed Web of Science ®Google Scholar
• Tuckermann J, Schilling AF, Priemel M et al. Glucocorticoid induced osteoporosis requires the glucocorticoid receptor in osteoblasts and does not depend on DNA binding of the receptor. ASBMR Meeting Nashville 1101 (2005).
   Google Scholar
• Khan SA, Kanis JA, Vasikaran S et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J. Bone Miner. Res. 12, 1700–1707 (1997).
   PubMed Web of Science ®Google Scholar
• Nancollas GH, Tang R, Phipps RJ et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone (2005) (In Press).
   PubMedGoogle Scholar
• Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J. Clin. Endocrinol. Metab. 90, 1294–1301 (2005).
   PubMed Web of Science ®Google Scholar